Clinical Cooperations
Translational Research at Helmholtz Zentrum München
The objective of translational research is to transfer knowlegde that has been acquired by basic research into practical use and turn it into innovation. Successful project development essentially relies on a value driven cooperation of different disciplines and a close exchange between basic scientists and clinicians.
Source: Halfpoint/ Fotolia
This interdisciplinary research approach is realized within Translational Research Centers and the following Clinical Cooperations:
Diabetes
Nutrigenomics and Type-2-Diabetes mellitus
Genetic risk variants for type-2-diabetes and obesity are functionally characterized to open up new strategies to prevent and treat type-2-diabetes and obesity.
Partner Institutions: Helmholtz Zentrum München, Technische Universität München, University Hospital rechts der Isar
Head: Prof. Dr. Hans Hauner
Tel. +49 8161 71-2000
E-mail
More information about CCG Nutrigenomics and Type-2-Diabetes mellitus
Biomarkers for the Subclassification of Type-2-Diabetes
Identification and validation of biomarkers to indicate an increased risk for type-2-diabetes in individuals with normal glucose metabolism.
Partner Institutions: Helmholtz Zentrum München, LMU University Hospital
Head: Prof. Dr. Jochen Seißler
Tel. +49 89 5160-2200
E-mail
More information about CCG Biomarkers for Subclassification of Type-2-Diabetes
Allergy
Clinical Allergology Unit
A birth cohort investigates the interactions and influences of the microbiome, the immune system along with environmental factors in the development of allergic diseases.
Partner Institutions: Helmholtz Zentrum München, University Hospital rechts der Isar
Head: Univ.-Prof. Dr. med. Tilo Biedermann
Tel. +49 89 4140-3170
E-mail
More Information about Clinical Allergy Unit (EKA)
Innovative Therapies
Personalized Radiotherapy in Head and Neck Cancer
Identification and validation of biomarkers of radiation sensitivity in HNSCC, in order to allow a stratification of patients prior to treatment for an improvement of personalized therapy concepts.
Partner Institutions: Helmholtz Zentrum München, LMU University Hospital.
Head: Prof. Dr. med. Claus Belka
Tel. +49 89 4400-74520
E-mail
More information about CCG Personalized Radiotherapy in Head and Neck Cancer
Clinical Pharmacology Unit
The immune response in a prospective observational cohort study after yellow fever vaccination is analysed. This approach is designed to identify genetic or phenotypic biomarkers that could predict the efficacy of yellow fever vaccination.
Partner Institutions: Helmholtz Zentrum München, LMU University Hospital
Head: Prof. Dr. med. Stefan Endres
Tel. +49 89 4400-57300
E-mail
